{"nctId":"NCT00536731","briefTitle":"Symbicort Rapihaler Therapeutic Equivalence Study","startDateStruct":{"date":"2007-09"},"conditions":["Bronchial Asthma"],"count":742,"armGroups":[{"label":"Symbicort pMDI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Symbicort pMDI"]},{"label":"Symbicort Turbuhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Symbicort Turbuhaler"]},{"label":"Pulmicort Turbuhaler","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pulmicort Turbuhaler"]}],"interventions":[{"name":"Symbicort Turbuhaler","otherNames":[]},{"name":"Symbicort pMDI","otherNames":[]},{"name":"Pulmicort Turbuhaler","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Asthma clinically diagnosed since at least 6 months.\n* Lung function values measured ≥ 50% and ≤ 90% of predicted normal.\n* Patients with reversible airway obstruction Daily use of inhaled steroids (any brand) for \\>3 months.\n\nExclusion Criteria:\n\n* Use of oral, rectal or parenteral steroids within 30 days prior to start of study.\n* Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to start of randomised treatment.\n* Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or the patient's ability to participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Morning Peak Expiratory Flow (PEF)","description":"Change in the Morning PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.88","spread":"24.6"},{"groupId":"OG001","value":"13.78","spread":"29.7"},{"groupId":"OG002","value":"4.59","spread":"27.9"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (PEF)","description":"Change in the Evening PEF from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomisation). No imputation of missing data was performed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.34","spread":"24.3"},{"groupId":"OG001","value":"10.80","spread":"29.1"},{"groupId":"OG002","value":"1.43","spread":"25.7"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score, Night","description":"Change in the Asthma Symptom Score (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.41"},{"groupId":"OG001","value":"-0.27","spread":"0.41"},{"groupId":"OG002","value":"-0.15","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score, Day","description":"Change in the Asthma Symptom Score (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.38"},{"groupId":"OG001","value":"-0.24","spread":"0.40"},{"groupId":"OG002","value":"-0.15","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Asthma Symptom Score, Total","description":"Change in the Asthma Symptom Score (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.73"},{"groupId":"OG001","value":"-0.51","spread":"0.75"},{"groupId":"OG002","value":"-0.30","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Percentage of Nights With Awakenings Due to Asthma","description":"Change in the Percentage of Nights With Awakenings Due to Asthma from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. The participants answered \"Yes\" or \"No\" whether she/he woke up during the night due to asthma.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"24.1"},{"groupId":"OG001","value":"-14.0","spread":"26.4"},{"groupId":"OG002","value":"-8.3","spread":"25.5"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication, Night","description":"Change in the Use of Rescue Medication (Night) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.64"},{"groupId":"OG001","value":"-0.39","spread":"0.76"},{"groupId":"OG002","value":"-0.19","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication, Day","description":"Change in the Use of Rescue Medication (Day) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.39"},{"groupId":"OG001","value":"-0.20","spread":"0.47"},{"groupId":"OG002","value":"-0.13","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Use of Rescue Medication, Total","description":"Change in the Use of Rescue Medication (Total) from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"0.89"},{"groupId":"OG001","value":"-0.58","spread":"1.09"},{"groupId":"OG002","value":"-0.32","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Percentage of Symptom-free Days","description":"Change in the Percentage of Symptom-free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Symptom-free Day: no symptoms (asthma symptom score=0) night and day, and no awakenings due to asthma.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"23.7"},{"groupId":"OG001","value":"15.3","spread":"24.5"},{"groupId":"OG002","value":"9.1","spread":"21.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Asthma Control Days","description":"Change in the Percentage of Symptom Control Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Asthma Control Day: no symptoms (asthma symptom score=0) night and day, no awakenings due to asthma, no rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"23.6"},{"groupId":"OG001","value":"15.1","spread":"24.4"},{"groupId":"OG002","value":"9.1","spread":"21.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Rescue Free Days","description":"Change in the Percentage of Rescue Free Days from baseline (calculated as a mean using all available data for the 10 last days of run-in period) to week 6 (calculated as a mean using all available data after randomization, with run-in values as covariate). No imputation of missing data was performed. Rescue-free Day defined as day and night with no use of rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"30.9"},{"groupId":"OG001","value":"26.2","spread":"30.7"},{"groupId":"OG002","value":"17.2","spread":"28.4"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1)","description":"Change in the FEV1from baseline to week 6 (calculated as a mean using all available data after randomization)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.095","spread":"0.328"},{"groupId":"OG001","value":"0.147","spread":"0.364"},{"groupId":"OG002","value":"0.112","spread":"0.326"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":253},"commonTop":[]}}}